Myocardial fibrosis in athletes:Current perspective by Małek, Łukasz A & Bucciarelli-Ducci, Chiara
                          Małek, Ł. A., & Bucciarelli-Ducci, C. (2020). Myocardial fibrosis in
athletes: Current perspective. Clinical cardiology, 43(8), 882-888.
https://doi.org/10.1002/clc.23360
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1002/clc.23360
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://doi.org/10.1002/clc.23360 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/
R E V I EW
Myocardial fibrosis in athletes—Current perspective
Łukasz A. Małek1,2 | Chiara Bucciarelli-Ducci3
1Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, Warsaw, Poland
2Msc in Sports Cardiology, St. George's University of London, London, UK
3Bristol Heart Institute, Bristol National Institute of Health Research (NIHR) Biomedical Research Centre, University Hospitals Bristol NHS Trust and University of
Bristol, Bristol, UK
Correspondence
Łukasz A. Małek, MD, PhD, Department of
Epidemiology, Cardiovascular Disease
Prevention and Health Promotion, National
Institute of Cardiology, Niemodlinska str
33, 04-635 Warsaw, Poland.
Email: lmalek@ikard.pl
Funding information
University of Bristol; University Hospitals
Bristol NHS Foundation Trust; Bristol National
Institute of Health Research
Abstract
Several previous studies suggested that prolonged and extensive physical activity might
lead to increased prevalence of myocardial fibrosis in athletes. The review summarizes
these studies focusing on common patterns of myocardial fibrosis observed in athletes,
their potential causes and significance. It also presents recent research on parametric imag-
ing shedding new light on diffuse myocardial fibrosis in athletes. Finally, it reviews how
these traditional and novel cardiac magnetic resonance (CMR) techniques can be incorpo-
rated in the diagnostic work up to differentiate athlete's heart from cardiomyopathies.
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1 | INTRODUCTION
Studies have shown that prolonged endurance exercise leads to marked
elevation of myocardial necrosis markers, brain natriuretic peptides and an
increase of inflammatory markers.1-3 The raise of biochemical markers is
directly proportional to the duration and intensity of exercise and inversely
proportional to the amount of prior training.1 Some imaging heart studies,
but not all,4 have shown that biochemical changes were accompanied by a
decrease of cardiac performance, particularly in relation to the right ventri-
cle5,6 and by signs of myocardial oedema.6 These alterations were shown
to be only transient and do not persist in a longer perspective.5,6 Impor-
tantly, none of those studies have shown any myocardial fibrosis related
to the studied endurance events.4-6 It was suggested that increase of tro-
ponin levels is due to release of cytosolic fraction of this marker without
compromise to cardiomyocates or that it is related to muscular fatigue or
even transient renal impairment and decreased troponin clearance.1 How-
ever, other studies demonstrated that some lifelong endurance athletes
might be at increased risk of ventricular arrhythmias originating from the
right ventricle.7,8 These observations were followed by a group of studies
suggesting increased prevalence of fibrosis in veteran athletes in compari-
son to sedentary controls of the same age, leading to the hypothesis that
prolonged endurance training, especially without adequate recovery may
predispose to myocardial fibrosis.8,9 Apart from the risk of arrhythmias,
the consequences of myocardial fibrosis may include increased myocardial
stiffness and local cardiac dysfunction.10
The aim of this review is to summarize current understanding of
the possible causes and significance of observed myocardial fibrosis in
athletes with new insight from recent studies on diffuse interstitial
myocardial fibrosis.
2 | CMR IN THE ASSESSMENT OF
FIBROSIS IN ATHLETES
2.1 | Focal fibrosis
The detection of myocardial fibrosis with CMR is performed after
the administration of a gadolinium-based contrast agent into an
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antecubital vein. The gadolinium-chelates contrast agents used in
CMR are mainly extracellular contrast agents, which have an initial rel-
ative short vascular phase, followed by an extracellular phase in which
the contrast agent diffuses in the interstitium. There is a typical
“washin” and “washout” contrast dynamics in different tissues, includ-
ing the myocardium.11 In the normal heart, the interstitial space
undergoes normal “washout” of the contrast agent with no contrast
accumulation. In the presence of myocardial injury or disease, the
extracellular space increases leading to delayed “washout” and con-
trast accumulation. Higher concentration of contrast agent decreases
T1 relaxation time of the studied tissue, thus changing its signal inten-
sity, which appears “bright” (hyperintense) as opposed to the normal
myocardium (hypointense). The technique used to image the heart
post contrast is called late gadolinium enhancement (LGE) and the
images are acquired 10 to 15 minutes postcontrast injection. The two
main LGE patterns are (a) “ischemic” type characterized by
subendocardial to transmural LGE corresponding to territories of cor-
onary artery supply and (b) “nonischemic” type characterized by mid-
wall or subepicardial location, either focal or patchy, as observed in a
range of cardiomyopathies, myocarditis or nonischemic myocardial
injury from other causes. While LGE can detect focal myocardial fibro-
sis, the technique cannot detect interstitial fibrosis.
2.2 | Diffuse fibrosis
Recent developments in CMR were focused on introduction to clinical
practice of sequences called CMR relaxometry (native T1-mapping
and extracellular volume [ECV] of distribution), which is able to detect
diffuse fibrosis.12 This technique is based on mapping of T1-relaxation
time of myocardium (measured in milliseconds), which varies in rela-
tion to the composition of myocardium and rises with the increase in
the amount of fibrotic tissue. Registration of T1-relaxation time maps
before and after contrast administration and knowledge of blood vis-
cosity affecting the T1 time (measured by patient's hematocrit) permit
calculation of ECV of the myocardium. As native (without contrast)
myocardial T1-mapping is believed to vary substantially between vari-
ous scanners, different contrast agents and T1-mapping sequences,
the ECV is believed to adjust for most of these differences and to
most reliably depict diffuse fibrosis.12-14 So far, most of the studies on
fibrosis in athletes with means of CMR were based only on LGE
detection9,15 but more recently there are studies incorporating
T1-mapping and ECV calculation.16-23 Findings from these studies will
be summarized below.
3 | COMMON PATTERNS OF
MYOCARDIAL FIBROSIS IN ATHLETES
Most of the studies on myocardial fibrosis in athletes were based on
middle age or veteran endurance athletes, both amateur and profes-
sional.9,15 These athletes are typically between 30 and 60 years of
age, predominantly male and have been engaging for at least 5 to
10 years in mainly endurance (running, biking, or combined) exercises.
The presented results should be therefore interpreted in this context.
Detailed analysis of studies on LGE detection in athletes has been
presented in earlier reviews.9,15 Therefore, here, only a concise sum-
mary of the observations will be provided. In general, in asymptomatic
endurance athletes with normal ECG three LGE patterns can be dis-
tinguished: two nonischemic and one ischemic. The nonischemic pat-
terns include: (a) mid-myocardial LGE in the insertion points (points in
the interventricular septum where right and left ventricle muscles
connect called otherwise “hinge points” or junction points) and
(b) subepicardial or mid-myocardial LGE in the inferolateral segments
or less commonly in the interventricular septum or elsewhere.
3.1 | Insertion point fibrosis
Insertion point fibrosis is most often limited to the inferior insertion
point (Figure 1A). It is the most commonly observed pattern in ath-
letes irrespective of age.9,15 Its prevalence may reach up to 20% to
30% and has been correlated with a cumulative training load and
training intensity.24 These correlations may reflect the time of pres-
sure and/or volume overload present in the right ventricle during
intensive exercise, which causes tension on the insertion points and
may lead to microinjuries visible later as spots of LGE in that loca-
tion.22 In line with this, similar pattern of fibrosis (however more likely
to involve both upper and lower insertion points) has been also
observed in patients with pulmonary hypertension or pulmonary
regurgitation after repair of tetralogy of Fallot.25-27 Importantly, in
both of those instances, this type of LGE was shown to be benign.
Another hypothesis suggests that insertion point fibrosis may be
related to myocardial hypertrophy visible in some athletes. Accord-
ingly, a similar pattern of fibrosis is also visible in patients with hyper-
trophic cardiomyopathy, but a large study found that contrary to
more pronounced LGE pattern, these small spots of insertion point
fibrosis also do not affect prognosis.28 Insertion point fibrosis has
been also observed in around 10% of otherwise healthy elderly indi-
viduals and may form one of the elements of an aging heart.22,29 A
recent study has found that in subjects without additional evidence of
cardiac damage insertion point fibrosis is to be considered an inciden-
tal finding.30
3.2 | Inferolateral or septal nonischemic fibrosis
Inferolateral and septal nonischemic fibrosis is less often observed in
athletes than insertion point fibrosis (Figure 1B). Inferolateral mid-
myocardial fibrosis has been previously noticed in some rare storage
diseases as Fabry disease,31 but is most characteristic of an acute or
healed myocarditis.11 It is therefore plausible that small, linear sub-
epicardial, or mid-myocardial areas of LGE in the inferolateral seg-
ments or in the interventricular septum in asymptomatic endurance
athletes reflect previous, usually silent, myocarditis. Intensive, pro-
longed exercise has been shown to affect immune resistance in the
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short period after intensive exercise, which if combined with seasonal
infections may predispose athletes to myocarditis.32,33 Although this
has been so far shown only in animal models, there are case reports
supporting this hypothesis.34,35 Myocarditis usually resolves without
complications and small remnant scars are considered benign and do
not require further testing. Such small, silent, mid-wall areas of fibrosis
have also been found in almost 4% of general population.36 Only if
they are larger and form striae of LGE, particularly in the anteroseptal
location, they may increase the risk of severe arrhythmias and affect
prognosis as demonstrated in several studies37-40. However, athletes
with large areas of postmyocarditis LGE are more likely to be symp-
tomatic and report palpitations or reduced physical performance or
present ECG and echocardiographic changes.37-39
In fact, recent study in a large community-based sample of older
adults from Reykjavik has demonstrated that such minor nonischemic
fibrosis patterns, as described in asymptomatic athletes, do not influ-
ence prognosis when adjusted for traditional risk factors.41
3.3 | Ischemic fibrosis
Ischemic fibrosis has been reported predominantly in athletes above
50 years of age (veteran athletes) and may reflect the lifelong influ-
ence of common cardiovascular risk factors present in these individ-
uals (Figure 1C). Exercise has many beneficial effects on the heart but
does not eliminate the presence of all risk factors of atherosclerosis.
In fact, the prevalence of common cardiovascular risk factors in Olym-
pic athletes was surprisingly high including 0.3% of hyperglycemia,
3.8% of hypertension, 8% of smoking habit, 18% of positive family
history, 25% of increased waist circumference, and 32% for dys-
lipidemia.42 In that study, endurance athletes had generally low car-
diovascular risk profile, but one to two risk factors were still present
in 50% of them and 2% of them had three to four risk factors. A
recent study demonstrated that veteran athletes have more coronary
atherosclerotic plaques than age and sex-matched sedentary con-
trols.43 These plaques may arise from increased shear stress during
periods of intensive exercise with elevated coronary pressures or
might be caused by transient periods of inflammation. However, the
morphology of plaques seems more stable (calcified) with lower prev-
alence of the soft, vulnerable plaques, which are prone to rupture.43
Nevertheless, as coronary plaques are present it seems logical that at
least some of them may occasionally erode causing small, silent myo-
cardial infarctions (Figure 1C). In fact, silent myocardial infarctions
were found not only in veteran athletes, but also in normal population.
The results of the MESA study have shown subendocardial (ischemic)
scars on CMR in 7.9% of people aged 68 ± 9.36 In most of them
(78%), these scars were not visible on electrocardiogram or by clinical
adjudication. Exploring the prevalence and size of silent ischemic scars
in veteran athletes and age and sex-matched sedentary controls could
clarify whether the scar burden is smaller in athletes. There is another
potential confounding factor, which should be added to the
equation—heterogeneity of the veteran athlete group. Some of those
athletes are lifelong sportsmen, while others engaged in regular exer-
cise in their mid-life. It is therefore possible that some events like the
diagnosis of risk factors or even an adverse cardiovascular event at
young age in a close family member may have influenced their deci-
sions. This would form a considerable inclusion bias, which needs to
be considered in future studies.
In summary, the most common patterns of LGE observed in ath-
letes with different training history and in sedentary controls in rela-
tion to age are summarized in Figure 2.
4 | NEW DATA FROM PARAMETRIC
IMAGING STUDIES
Only a few recent studies on diffuse fibrosis in athletes can be
found.16-23 They are summarized in Table 1. In general, there is a large
F IGURE 1 Most common patterns of late gadolinium enhancement (LGE) observed in athletes. A,Short axis view, mid-myocardial
(nonischemic) LGE in the inferior insertion point in an asymptomatic 41-year-old ultramarathon runner without prior medical history (own
data), B, three-chamber view, mid-myocardial (nonischemic) LGE in the basal inferolateral segment in an asymptomatic 41-year-old ultramarathon
runner without prior medical history (own data), C, short axis view, subendocardial (ischemic) LGE in the mid inferolateral segment in an
asymptomatic 52-year-old recreational runner without prior medical history (own data)
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discrepancy between those studies in terms of scanners and
sequences used to analyze T1-mapping, as well as in the use of con-
trast agent and therefore concomitant LGE reporting (some were
based only on native T1-mapping).17 The native T1 time in athletes
varies from 943 to 1268 ms and ECV from 20% to 26%. Therefore,
each result should be interpreted in relation to internal control group
of healthy individuals and dedicated reference values.12-14 Most of
the studies demonstrate that endurance exercise does not lead to an
increase of ECV or is related to only slight increase, with absolute
values remaining within the reference range for the normal popula-
tion.18-22 Two studies reported a decrease of ECV in athletes, which
is explained by increase of cardiomyocyte mass rather than ECV in
relation to training.16,23 In one of those studies, ECV inversely corre-
lated with increasing left ventricular mass.16 Interestingly, one study
reported increased ECV values in the remote myocardium of athletes
with concomitant LGE, suggesting that fibrosis might not be limited to
the macroscopically visible areas of nonischemic LGE in these
individuals.19
5 | MYOCARDIAL FIBROSIS IN ATHLETES;
DISTINGUISHING NORMAL FROM
ABNORMAL PATTERNS
All of the above considerations were based on observations made in
asymptomatic athletes. However, CMR is currently a well-established
second-line imaging test (after echocardiography) in athletes with
specified cardiomyopathy. Several features differentiating athlete's
heart and various cardiomyopathies have been proposed and are sum-
marized in Table 2 along with CMR characteristics of the athlete's
heart.44,45 In all conditions LGE detection and its pattern may be of
paramount relevance to the diagnosis and management. Recently, also
parametric imaging including T1-mapping and ECV calculation have
been used to detect diffuse fibrosis in at least some cardiomyopathies
such as hypertrophic cardiomyopathy (HCM) and dilated cardiomyop-
athy.12 Presence of LGE in locations not observed in athletes or larger
areas of LGE together with increase in T1-mapping time and ECV are
some of the features, which may help to differentiate cardiomyopathy
from the athlete's heart.
If fibrosis is detected we propose the following management
strategy. Only the detection of small insertion point fibrosis does not
seem to require further evaluation. Presence of fibrosis extending
beyond the insertion points in the interventricular septum or fibrosis
elsewhere in the myocardium regardless of its pattern should prompt
further evaluation, especially in the younger athlete age group. The
index of suspicion, regarding potential cardiac disease, should increase
if abnormal ECG or the presence of arrhythmias accompanies the
detection of fibrosis.
6 | GAPS IN RESEARCH
Further studies are needed to comprehensively analyze not only the
presence, but also the relation between different patterns and amount
F IGURE 2 Most common patterns of late gadolinium enhancement (LGE) observed in athletes with different training history and in sedentary
controls in relation to age. All drawings of the left ventricle are in short axis. Three groups are presented: on the left—lifelong athletes who start
early in life mainly during adolescence (<20 years of age) and eventually become active or sedentary veteran athletes; in the middle—athletes who
start later in life (>20-30 years of age) and continue to become veteran athletes; on the right—sedentary controls. Patterns of fibrosis are
described in text and presented in Figure 1. Studies demonstrate that most common patterns of fibrosis in athletes are insertion point fibrosis and
myocarditis-type fibrosis.16,18,19,21,22,24 However, both of those patterns were also found in sedentary individuals.22,29,30,36 Insertion point
fibrosis seems both age and training related and therefore may occur earlier in athletes.5,22,24 Ischemic fibrosis was occasionally found with similar
frequency in veteran athletes9 and sedentary individuals36




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































886 MAŁEK AND BUCCIARELLI-DUCCI
of LGE in asymptomatic athletes and arrhythmia burden. Also, there is
no data on factors potentially predisposing athletes to fibrosis includ-
ing certain types of training, number of years or intensity of exercise
or sex predominance. Furthermore, it should be acknowledged that
the studies presented in the review are all cross sectional in nature.
There is still a need for large longitudinal studies with clinical end
points to draw final conclusions.
7 | CONCLUSIONS
Studies on myocardial fibrosis in endurance athletes demonstrate that
this form of sport activity does not lead to diffuse fibrosis of the myocar-
dium. However, in some athletes, nonischemic foci of fibrosis may be
observed, but are mainly limited to insertion points. Endurance athletes
may be also more prone to myocarditis (often silent), which is usually
detected by visualization of small nonischemic scars. It is also doubtful
that endurance activity increases the risk of ischemic fibrosis beyond that
which can be explained by age and the presence of common cardiovas-
cular risk factors. The low risk profile of myocardial fibrosis in otherwise
asymptomatic patients is supported by the recent large-scale observa-
tions that a mid-life cardiorespiratory fitness inversely correlated with
long-term risk of mortality and that intensive and vigorous physical activ-
ity does not seem to increase the risk of ventricular arrhythmias.46,47
Based on current evidence, increased availability and use of CMR
is likely to identify small volume of scar of uncertain significance in a
considerable proportion of athletes. As such, CMR should be reserved
for individuals with high index of suspicion for cardiac disease, includ-
ing athletes with clinical symptoms or abnormalities on first-line inves-
tigations, as it may elucidate diagnosis and direct management.
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